Patent 10952998 was granted and assigned to Silvergate Pharmaceuticals, Inc. on March, 2021 by the United States Patent and Trademark Office.
Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).